Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 4 2Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia 4Leukemia, Myeloid, Chronic-Phase 2Gastrointestinal Stromal Tumors 2Blast Crisis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Philadelphia Chromosome 1Myeloproliferative Disorders 1

Interventions

nilotinib 2Sunitinib 2Imatinib Mesylate 2regorafenib 1avapritinib 1Oxaliplatin 1Midazolam 1Lead 1Esomeprazole 1Erlotinib Hydrochloride 1Caffeine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Gastrointestinal Stromal Tumors × nilotinib × Clear all
NCT00756509 2026-01-20

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Novartis

Phase 4 Completed
34 enrolled 11 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01735955 2024-02-08

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Novartis

Phase 4 Completed
57 enrolled 8 charts
GastrointestinalLymphoidMyeloidOther hematologic neoplasmSarcoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Piebaldism, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡